Detail akcie Biomea Fusion Rg online

Business Summary: Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Biomea Fusion Inc revenues was not reported. Net loss decreased 39% to $66.4M. Lower net loss reflects Developing clinical products segment loss decrease of 37% to $71.8M, United States segment loss decrease of 37% to $71.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.03 to -$1.58.